Literature DB >> 23315387

Heterogeneous expression of CT10, CT45 and GAGE7 antigens and their prognostic significance in human breast carcinoma.

Xingchun Zhou1, Fan Yang, Tao Zhang, Ran Zhuang, Yuanjie Sun, Liang Fang, Chunmei Zhang, Ying Ma, Gaosheng Huang, Fucheng Ma, Chaojun Song, Boquan Jin.   

Abstract

OBJECTIVE: The goal of this study was to detect the intertumoral heterogeneity of CT10, CT45 and GAGE7 expression and further to analyze their prognostic value.
METHODS: The intertumoral heterogeneity of three cancer/testis antigens was examined by immunohistochemistry using 120 samples from patients with infiltrating ductal breast carcinoma. The expression patterns were classified and correlated with the clinicopathologic variables and outcome of the patients.
RESULTS: CT10 showed punctate, focal and diffuse expression patterns according to the characteristic of its distribution. CT45 showed cytoplasmic, nuclear or combined cytoplasmic and nuclear expression patterns according to its subcellular location. GAGE7 exhibited nuclear, cytoplasmic and nucleolar expression patterns. Three cancer/testis antigens were also observed coordinately expressed in infiltrating ductal breast carcinoma. Patients with tumors with CT10 expression was significantly correlated with nodal metastases (P < 0.001) and advanced clinical stages (P = 0.001). Patients with tumors with cytoplasmic GAGE7 and with the expression of two or more cancer/testis antigens were significantly correlated with advanced clinical stages (P = 0.001 and P = 0.030). No significant difference was identified between the different expression patterns of CT45 and clinicopathologic variables. In addition, Kaplan-Meier analysis revealed that diffuse CT10 expression and coexpression of three cancer/testis antigens were related to the poor prognosis of patients with infiltrating ductal breast carcinoma.
CONCLUSIONS: Diffuse CT10 expression and the coexpression of three cancer/testis antigens can be used as a biomarker to distinguish patients with a poorer outcome of the breast carcinoma. Our finding may provide useful data for evaluating the prognosis of this disease and improving the effectiveness of therapeutic application based on the three cancer/testis antigens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23315387     DOI: 10.1093/jjco/hys236

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  9 in total

1.  Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.

Authors:  Jun Yao; Otavia L Caballero; W K Alfred Yung; John N Weinstein; Gregory J Riggins; Robert L Strausberg; Qi Zhao
Journal:  Cancer Immunol Res       Date:  2013-11-25       Impact factor: 11.151

2.  Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.

Authors:  Kunio Iura; Kenichi Kohashi; Nobuko Yasutake; Takeaki Ishii; Akira Maekawa; Hirofumi Bekki; Hiroshi Otsuka; Yuichi Yamada; Hidetaka Yamamoto; Yoshihiro Ohishi; Yoshihiro Matsumoto; Yukihide Iwamoto; Yoshinao Oda
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

3.  Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.

Authors:  Chen Chen; Dan Gao; Jinlong Huo; Rui Qu; Youming Guo; Xiaochi Hu; Libo Luo
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

4.  MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis.

Authors:  Fan Yang; Xingchun Zhou; Xia Miao; Tao Zhang; Xiaojun Hang; Ru Tie; Nan Liu; Fei Tian; Fuli Wang; Jianlin Yuan
Journal:  Breast Cancer Res Treat       Date:  2014-04-01       Impact factor: 4.872

5.  CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis.

Authors:  B Shang; A Gao; Y Pan; G Zhang; J Tu; Y Zhou; P Yang; Z Cao; Q Wei; Y Ding; J Zhang; Y Zhao; Q Zhou
Journal:  Cell Death Dis       Date:  2014-06-05       Impact factor: 8.469

6.  YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer.

Authors:  Izumi Suzuki; Sachiko Yoshida; Kouichi Tabu; Soshi Kusunoki; Yumiko Matsumura; Hiroto Izumi; Kazuo Asanoma; Hiroshi Yagi; Ichiro Onoyama; Kenzo Sonoda; Kimitoshi Kohno; Tetsuya Taga; Atsuo Itakura; Satoru Takeda; Kiyoko Kato
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

7.  CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through β-catenin.

Authors:  Mingxin Wen; Hui Ren; Shouqiang Zhang; Tao Li; Jiefeng Zhang; Peng Ren
Journal:  Cell Death Dis       Date:  2021-06-25       Impact factor: 8.469

8.  CT45A1 siRNA silencing suppresses the proliferation, metastasis and invasion of lung cancer cells by downregulating the ERK/CREB signaling pathway.

Authors:  Feng Tang; Shengjun Tang; Xiaolong Guo; Chao Yang; Ke Jia
Journal:  Mol Med Rep       Date:  2017-09-12       Impact factor: 2.952

9.  Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome.

Authors:  Shaolei Li; Yuanyuan Ma; Ying Xiong; Panpan Zhang; Xiao Wang; Yong Wang; Yue Yang
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.